Reoccurrence of takotsubo cardiomyopathy induced by osimertinib: A case report.

Autor: Fukuda Y; Division of Onco-cardiology Hyogo cancer center Akashi Japan., Kawa Y; Division of Respiratory Medicine Hyogo cancer center Akashi Japan., Nonaka A; Division of Onco-cardiology Hyogo cancer center Akashi Japan., Shiotani H; Division of Health Sciences, Department of Nursing Kobe Tokiwa University Kobe Japan.
Jazyk: angličtina
Zdroj: Clinical case reports [Clin Case Rep] 2022 Sep 02; Vol. 10 (9), pp. e6279. Date of Electronic Publication: 2022 Sep 02 (Print Publication: 2022).
DOI: 10.1002/ccr3.6279
Abstrakt: A patient with lung cancer was administrated osimertinib. She developed symptomatic heart failure due to Takotsubo cardiomyopathy (TC). As her condition improved after discontinuing osimertinib, TC was thought to be caused by osimertinib. Reoccurrence of TC was seen after readministrating half dose of osimertinib.
Competing Interests: None declared.
(© 2022 The Authors. Clinical Case Reports published by John Wiley & Sons Ltd.)
Databáze: MEDLINE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje